Pharma Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Celgene Corporation
Revlimid evaluated as combination oral treatment regimen in newly diagnosed multiple myeloma
July 4th, 2006
Celgene Corporation (CELG) announced that clinical data from a study with combination therapy lenalidomide (Revlimid), melphalan and prednisone (R-MP) in elderly newly diagnosed multiple myeloma patients show that after seven treatment cycles with R-MP all patients showed a response with no further disease progressions observed, and event-free survival (EFS) (p<0.001) after 9.6 month of follow-up. Results were reported at an oral presentation during the 42nd American Society of Clinical Oncology (ASCO) Meeting. Revlimid is now approved by the U.S. Food and Drug Administration (FDA) for treatment of patients with transfusion-dependent anemia due to...
Source: Pharma Law Weekly (2006-07-04)
|
